Jazieh Khalid A, Foote Michael B, Diaz Luis A
The Swim Across America Laboratory, The Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, MD; The Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
The Swim Across America Laboratory, The Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, MD; The Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Semin Radiat Oncol. 2014 Apr;24(2):67-76. doi: 10.1016/j.semradonc.2013.11.007.
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States and survival rates have seen minimal improvement over the past few decades. Although results are poor, surgical resection is considered the only curative therapeutic intervention for pancreatic cancer, thereby emphasizing the significance of effective diagnostic and prognostic tools to improve outcomes. As such, biomarkers play a promising role in the development of personalized treatments for patients with pancreatic cancer. Prognostic biomarkers, such as serum carbohydrate antigen 19-9 in particular, as well as cancer stem cell markers, provide valuable insight into the biological processes of an individual and their likely course of disease. This, consequently, allows for the assessment of optimal therapeutic intervention. Furthermore, current efforts target putative predictive biomarkers such as BRCA2, PALB2, and SPARC so as to determine their influence on tumor response on targeted therapies. As research progresses, more evidence will provide clinicians with guidelines on the utilization of biomarkers to accurately stage and tailor personalized treatment to the needs of specific patients with pancreatic cancer.
胰腺癌是美国癌症相关死亡的第四大主要原因，在过去几十年中生存率几乎没有改善。尽管治疗结果不佳，但手术切除被认为是胰腺癌唯一的治愈性治疗干预措施，因此强调了有效诊断和预后工具对改善治疗结果的重要性。因此，生物标志物在胰腺癌患者个性化治疗的发展中发挥着有前景的作用。预后生物标志物，特别是血清糖类抗原19-9以及癌症干细胞标志物，为个体的生物学过程及其可能的疾病进程提供了有价值的见解。这进而有助于评估最佳治疗干预措施。此外，目前的研究致力于寻找如BRCA2、PALB2和SPARC等假定的预测生物标志物，以确定它们对靶向治疗中肿瘤反应的影响。随着研究的进展，更多证据将为临床医生提供关于利用生物标志物准确分期和根据特定胰腺癌患者的需求定制个性化治疗的指导方针。
